Bad Homburg (November 19, 2024) – Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced its heart and lung group has been awarded a national group purchasing agreement for Mechanical Circulatory Support with Premier, Inc in the U.S.

巴德洪堡（2024年11月19日）–世界领先的肾脏疾病患者产品和服务提供商费森尤斯医疗（FME）今天宣布，其心肺集团已获得与美国Premier，Inc.签订的机械循环支持国家集团采购协议。

Since acquiring Xenios in 2016, Fresenius Medical Care has been dedicated to advancing heart and lung therapy. The agreement underscores FME’s commitment to critical care solutions and allows Premier member hospitals and health systems, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the Novalung System..

自2016年收购Xenios以来，费森尤斯医疗一直致力于推进心肺治疗。该协议强调了FME对重症监护解决方案的承诺，并允许Premier成员医院和卫生系统自行决定利用Premier为Novalung系统预先协商的特殊定价和条款。。

'We are excited to be awarded this agreement by Premier, which will help broaden the reach of our Novalung ECMO System,' said Olaf Schermeier, PhD, Chief Executive Officer, Critical Care & Ventures at Fresenius Medical Care. 'This agreement highlights our dedication to delivering safe, simple, and portable solutions and enhancing patient outcomes in critical care units in the United States.

该协议强调了我们致力于在美国重症监护病房提供安全、简单和便携的解决方案，并提高患者的治疗效果。

Through our agreement with Premier, we aim to better serve healthcare providers with efficient heart and lung support therapy, helping to improve survival rates and recovery for patients with severe cardiac or pulmonary failure. The rapidly shifting market dynamics may increase risks to hospitals, and this agreement provides broader access with the Novalung System for ECMO.'.

通过与Premier的协议，我们的目标是更好地为医疗保健提供者提供有效的心肺支持治疗，帮助提高严重心衰或肺衰竭患者的生存率和康复率。快速变化的市场动态可能会增加医院的风险，该协议为ECMO提供了更广泛的Novalung系统。

The Novalung System for extracorporeal membrane oxygenation (ECMO), was the first system FDA-cleared for long-term (>6hr) ECMO, providing a critical offering to patients and hospitals. The system pumps and oxygenates the blood of patients with acute respiratory failure or acute cardiopulmonary failure.

用于体外膜肺氧合（ECMO）的Novalung系统是FDA批准的第一个长期（>6小时）ECMO系统，为患者和医院提供了关键服务。该系统对急性呼吸衰竭或急性心肺衰竭患者的血液进行泵送和充氧。

Novalung offers a portable therapy solution designed to improve clinical outcomes and accommodate various clinical care settings such as intensive care units, operating rooms, cardiac catheterization labs and emergency departments..

Novalung提供便携式治疗解决方案，旨在改善临床效果，并适应各种临床护理环境，如重症监护室、手术室、心导管插入术实验室和急诊室。。

Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost..

Premier是一家领先的医疗保健改进公司，联合了约4350家美国医院和300000家其他供应商的联盟，以改变医疗保健。凭借集成的数据和分析、协作、供应链解决方案、咨询和其他服务，Premier能够以较低的成本实现更好的护理和结果。。